After causing a rumpus last week when a staging website went live unexpectedly before Amarin got the official nod from the US FDA for an experimental fish oil pill, the firm revealed after the bell on 26 July that it had indeed been granted the OK to market the drug in the US under the brand name Vascepa.
The drug, formerly known as AMR101, is a semisynthetic, 96% ultra-pure ethyl ester of eicosapentaenoic acid that will be sold...







